UY24888A1 - Tabletas de oxacarbazepina recubiertas de pelicula - Google Patents

Tabletas de oxacarbazepina recubiertas de pelicula

Info

Publication number
UY24888A1
UY24888A1 UY24888A UY24888A UY24888A1 UY 24888 A1 UY24888 A1 UY 24888A1 UY 24888 A UY24888 A UY 24888A UY 24888 A UY24888 A UY 24888A UY 24888 A1 UY24888 A1 UY 24888A1
Authority
UY
Uruguay
Prior art keywords
oxacarbazepine
tablets
film coated
formulations
coated tablets
Prior art date
Application number
UY24888A
Other languages
English (en)
Inventor
Dr Burkhard Schlutermann
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=4184588&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY24888(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of UY24888A1 publication Critical patent/UY24888A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/18—Dibenzazepines; Hydrogenated dibenzazepines
    • C07D223/22—Dibenz [b, f] azepines; Hydrogenated dibenz [b, f] azepines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Abstract

La invención se refiere a formulaciones, por ejemplo tabletas recubiertas de películas que contienen oxacarbazepina, y a procesos para la producción de estas formulaciones. Las tabletas recubiertas de película tienen un núcleo de tabletas que comprende una dosis terapéuticamente efectiva de oxacarbazepina, que está en una forma finamente molida, que tiene un tamano de partículas promedio de 4 a 12 micras, y un recubrimiento externo hidrófilico permeables.
UY24888A 1997-02-14 1998-02-13 Tabletas de oxacarbazepina recubiertas de pelicula UY24888A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH33197 1997-02-14

Publications (1)

Publication Number Publication Date
UY24888A1 true UY24888A1 (es) 2000-12-29

Family

ID=4184588

Family Applications (1)

Application Number Title Priority Date Filing Date
UY24888A UY24888A1 (es) 1997-02-14 1998-02-13 Tabletas de oxacarbazepina recubiertas de pelicula

Country Status (32)

Country Link
US (2) US20070036863A1 (es)
EP (1) EP0966287B1 (es)
JP (3) JP2000511935A (es)
KR (3) KR19980071337A (es)
CN (2) CN1170542C (es)
AR (1) AR011142A1 (es)
AT (1) ATE239481T1 (es)
AU (1) AU738030B2 (es)
BR (1) BR9807368A (es)
CA (1) CA2277791C (es)
CO (1) CO4920215A1 (es)
CY (1) CY2480B1 (es)
CZ (1) CZ298840B6 (es)
DE (1) DE69814367T2 (es)
DK (1) DK0966287T3 (es)
ES (1) ES2199422T3 (es)
HK (1) HK1024423A1 (es)
HU (1) HU227807B1 (es)
ID (1) ID22348A (es)
MY (1) MY117582A (es)
NO (1) NO327486B1 (es)
NZ (1) NZ336946A (es)
PE (1) PE58999A1 (es)
PL (1) PL193332B1 (es)
PT (1) PT966287E (es)
RU (1) RU2201218C2 (es)
SK (1) SK284503B6 (es)
TR (1) TR199901804T2 (es)
TW (1) TW529957B (es)
UY (1) UY24888A1 (es)
WO (1) WO1998035681A1 (es)
ZA (1) ZA981205B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO4920215A1 (es) * 1997-02-14 2000-05-29 Novartis Ag Tabletas de oxacarbazepina recubiertas de una pelicula y metodo para la produccion de estas formulaciones
GB9925962D0 (en) * 1999-11-02 1999-12-29 Novartis Ag Organic compounds
US6368628B1 (en) * 2000-05-26 2002-04-09 Pharma Pass Llc Sustained release pharmaceutical composition free of food effect
AU2002348884A1 (en) 2001-12-21 2003-07-09 Pfizer Products Inc. Directly compressible formulations of azithromycin
GB0221956D0 (en) * 2002-09-20 2002-10-30 Novartis Ag Organic compounds
RU2369393C2 (ru) 2003-09-03 2009-10-10 Новартис Аг Применение окскарбазепина для лечения диабетической нейропатической боли и для улучшения сна
AR048318A1 (es) * 2004-03-22 2006-04-19 Novartis Ag Formulaciones de matriz orales que comprenden licarbazepina
AR048672A1 (es) * 2004-03-22 2006-05-17 Novartis Ag Tabletas de desintegracion que comprenden licarbazepina
US8367105B2 (en) 2004-11-10 2013-02-05 Teva Pharmaceutical Industries, Ltd. Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby
US20060252745A1 (en) 2005-05-06 2006-11-09 Almeida Jose L D Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
DK1928427T3 (da) 2005-09-23 2010-03-08 Hoffmann La Roche Hidtil ukendt dosisformulering
ES2439736T3 (es) 2005-11-08 2014-01-24 Vertex Pharmaceuticals Incorporated Moduladores heterocíclicos de transportadores de casete de unión a ATP
AU2006313009B2 (en) * 2005-11-10 2013-10-24 Alphapharm Pty Ltd Process to control particle size
EP1951197A4 (en) * 2005-11-10 2011-12-21 Alphapharm Pty Ltd METHOD OF CHECKING THE PARTICLE SIZE
AU2007211210A1 (en) * 2006-01-31 2007-08-09 Teva Pharmaceutical Industries Ltd. Oxcarbazepine pharmaceutical formulation and its method of preparation, wherein oxcarbazepine has a broad and multi-modal particle size distribution
WO2007089247A1 (en) * 2006-01-31 2007-08-09 Teva Pharmaceutical Industries Ltd. Oxcarbazepine pharmaceutical formulation and its method of preparation, wherein oxcarbazepine has a broad and multi-modal particle size distribution
WO2007121523A1 (en) * 2006-04-21 2007-11-01 Alphapharm Pty Ltd Pharmaceutical compositions of oxcarbazepine with a median particle size of 15 to 30 microns
EP2359830B1 (en) * 2006-04-26 2012-09-19 Supernus Pharmaceuticals, Inc. Controlled released preparations of oxcarbazepine having sigmoidal release profile
WO2007122635A2 (en) 2006-04-26 2007-11-01 Astron Research Limited Controlled release formulation comprising anti-epileptic drugs
US20080138403A1 (en) * 2006-12-08 2008-06-12 Sun Pharmaceutical Industries Ltd. Pharmaceutical dosage forms of oxcarbazepine
EP2476418A1 (en) 2006-12-21 2012-07-18 Alphapharm Pty Ltd. Pharmaceutical compound and composition for use in treating type II diabetes comprising rosiglitazone in a specific particle size
GB0700773D0 (en) 2007-01-15 2007-02-21 Portela & Ca Sa Drug therapies
EP1970056A1 (en) * 2007-03-15 2008-09-17 Polichem S.A. Time-specific delayed/pulsatile release dosage forms
EP2146699A2 (en) * 2007-05-23 2010-01-27 Ratiopharm GmbH Pharmaceutical compositions comprising oxcarbazepine
US8372431B2 (en) 2007-10-26 2013-02-12 Bial-Portela & C.A., S.A. Pharmaceutical composition comprising licarbazepine acetate
CN101910156B (zh) 2007-12-07 2013-12-04 沃泰克斯药物股份有限公司 3-(6-(1-(2,2-二氟苯并[d][1,3]间二氧杂环戊烯-5-基)环丙烷甲酰氨基)-3-甲基吡啶-2-基)苯甲酸的固体形式
DK3150198T3 (da) 2010-04-07 2021-11-01 Vertex Pharma Farmaceutiske sammensætninger af 3-(6-(1-(2,2-difluorbenzo[d][1,3]dioxol-5-yl)-cyclopropancarboxamido)-3-methylpyriodin-2-yl)benzoesyre og indgivelse deraf
US10231932B2 (en) 2013-11-12 2019-03-19 Vertex Pharmaceuticals Incorporated Process of preparing pharmaceutical compositions for the treatment of CFTR mediated diseases
CN103735527B (zh) * 2013-12-24 2014-09-10 武汉人福药业有限责任公司 一种奥卡西平片剂及其制备方法
WO2018208242A1 (en) 2017-05-10 2018-11-15 İlko Ilaç Sanayi Ve Ticaret Anonim Şirketi Formulation of deferasirox tablet for oral suspension composition with better processability

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI75561C (fi) * 1979-10-30 1988-07-11 Ciba Geigy Ag Foerfarande foer framstaellning av 5- karbamoyl-10-oxo-10,11-dihydro-5h-dibens/b,f/azepin och daertill noedvaendiga mellanprodukter.
CH649080A5 (de) * 1981-04-16 1985-04-30 Ciba Geigy Ag 5h-dibenz(b,f)azepin-5-carboxamide als mittel zur prophylaxe und behandlung von zerebraler leistungsinsuffizienz.
US4609675A (en) * 1984-08-17 1986-09-02 The Upjohn Company Stable, high dose, high bulk density ibuprofen granulations for tablet and capsule manufacturing
JPS6257467A (ja) * 1985-09-06 1987-03-13 Asahi Glass Co Ltd コ−テイング剤組成物
GB8524001D0 (en) * 1985-09-30 1985-11-06 Glaxo Group Ltd Pharmaceutical composition
CH668187A5 (de) * 1986-08-07 1988-12-15 Ciba Geigy Ag Therapeutisches system mit systemischer wirkung.
DD295760A5 (de) * 1989-01-31 1991-11-14 Martin-Luther-Universitaet Halle Wittenberg,De Arzneistoffreigabesystem mit kotrollierter wirkstoffreisetzung
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5231089A (en) * 1991-12-02 1993-07-27 University Of Florida Method of improving oral bioavailability of carbamazepine
FR2699077B1 (fr) * 1992-12-16 1995-01-13 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement de lésions neurologiques liées à des traumatismes.
FR2702148B1 (fr) * 1993-03-05 1995-04-07 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement du neuro-sida.
US5472714A (en) * 1993-09-08 1995-12-05 Ciba-Geigy Corporation Double-layered oxcarbazepine tablets
ZA953078B (en) * 1994-04-28 1996-01-05 Alza Corp Effective therapy for epilepsies
US5478654A (en) * 1994-05-06 1995-12-26 Gencorp Inc. Solventless carboxylated butadiene-vinylidene chloride adhesives for bonding rubber to metal
US5980942A (en) * 1997-01-23 1999-11-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Zero-order sustained release matrix tablet formulations of carbamazepine
US6296873B1 (en) * 1997-01-23 2001-10-02 Yissum Research Development Company Of The Hebrew University Of Jerusalem Zero-order sustained release delivery system for carbamazephine derivatives
CO4920215A1 (es) * 1997-02-14 2000-05-29 Novartis Ag Tabletas de oxacarbazepina recubiertas de una pelicula y metodo para la produccion de estas formulaciones

Also Published As

Publication number Publication date
ZA981205B (en) 1998-08-14
WO1998035681A1 (en) 1998-08-20
NZ336946A (en) 2001-02-23
DE69814367T2 (de) 2004-02-26
CZ287999A3 (cs) 1999-11-17
CA2277791A1 (en) 1998-08-20
PT966287E (pt) 2003-09-30
PL334959A1 (en) 2000-03-27
CN1247471A (zh) 2000-03-15
TW529957B (en) 2003-05-01
SK284503B6 (sk) 2005-05-05
SK109899A3 (en) 2000-03-13
AU738030B2 (en) 2001-09-06
CO4920215A1 (es) 2000-05-29
AR011142A1 (es) 2000-08-02
AU6622298A (en) 1998-09-08
CY2480B1 (en) 2005-06-03
NO993919L (no) 1999-08-13
DK0966287T3 (da) 2003-08-25
EP0966287A1 (en) 1999-12-29
TR199901804T2 (xx) 1999-09-21
ID22348A (id) 1999-09-30
EP0966287B1 (en) 2003-05-07
HUP0000886A2 (hu) 2000-09-28
NO993919D0 (no) 1999-08-13
HK1024423A1 (en) 2000-10-13
MY117582A (en) 2004-07-31
PE58999A1 (es) 1999-06-25
DE69814367D1 (de) 2003-06-12
CN1626093A (zh) 2005-06-15
KR20120079826A (ko) 2012-07-13
CZ298840B6 (cs) 2008-02-20
RU2201218C2 (ru) 2003-03-27
PL193332B1 (pl) 2007-02-28
US20080014269A1 (en) 2008-01-17
ES2199422T3 (es) 2004-02-16
HU227807B1 (en) 2012-03-28
JP2000511935A (ja) 2000-09-12
CN1170542C (zh) 2004-10-13
NO327486B1 (no) 2009-07-13
JP2010132694A (ja) 2010-06-17
KR20090037873A (ko) 2009-04-16
CA2277791C (en) 2008-11-18
KR19980071337A (ko) 1998-10-26
US20070036863A1 (en) 2007-02-15
HUP0000886A3 (en) 2002-10-28
JP2006077029A (ja) 2006-03-23
ATE239481T1 (de) 2003-05-15
BR9807368A (pt) 2000-03-14

Similar Documents

Publication Publication Date Title
UY24888A1 (es) Tabletas de oxacarbazepina recubiertas de pelicula
NO973840D0 (no) Doseringsform for avgivelse av et aktivt middel
NO992907D0 (no) Flat legemiddeltilberedning for applikasjon og frigiving av buprenorfin eller et annet farmakologisk sammenlignbart stoff i munnhulen og fremgangsmÕte for dens fremstilling
ATE233604T1 (de) Elektrostatische beschichtung
ATE332126T1 (de) Geschmacksmaskierte pharmazeutische zusammensetzungen
WO2002072034A3 (en) Chronotherapeutic dosage forms
AR002275A1 (es) Forma de dosificacion farmaceutica oral, procedimiento para la manufactura de una forma de dosificacion fija, y uso de dicha forma de dosificacionfarmaceutica oral.
MX9305438A (es) Perlas que tienen un nucleo revestido con un agente antimicotico y un polimero.
NZ512683A (en) Taste-masked pharmaceutical particles that are suitable for making chewable tablets
ES2172239T3 (es) Sistema osmotico de liberacion de farmacos.
CO5150154A1 (es) Composicion de sustrato y metodo para usarlo para el secuestro de irritantes de la piel
SE9704869D0 (sv) New pharmaceutical formulaton II
MX9604497A (es) Nueva formulacion farmaceutica y procedimiento.
AR005282A1 (es) Composición farmacéutica oral en la forma de un comprimido de unidades múltiples, uso de la misma para la preparación de medicamnetos, y procedimiento para su manufactura.
AR014467A1 (es) Unidad de dosis farmaceutica oralmente administrable de un tamano superior a 7 mm que comprende una droga y un recubrimiento externo, un metodo paraseparar una unidad de dosis farmaceutica oralmente administrable a partir de un alimento co-administrado y el uso de una droga y un material de recubrim
FI980822A0 (fi) Farmaseuttinen koostumus vaikuttavan aineen iho- tai limakalvopintaan tai iho- tai limakalvopinnan läpi
NO20005394L (no) Legemiddelavleveringssammensetninger bestående av klebende mikrosfærer
FR2774288B1 (fr) Microgranules d'omeprazole gastroproteges, procede d'obtention et preparations pharmaceutiques
DZ3473A1 (fr) Formulation pharmaceutique a liberation prolongee independante de la force ionique.
DK1077680T3 (da) Fremgangsmåde til fremstilling af en med bånd forsynet aktivt-stof-doseringsform til prolongeret release
ECSP982406A (es) Tabletas de oxacarbazepina recubiertas de pelicula
ITMI950625A0 (it) Composizione farmaceutica attiva nella cura di affezioni dermatologiche

Legal Events

Date Code Title Description
VENC Patent expired

Effective date: 20180213